Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZM001 in refractory systemic lupus erythematosus
NCT06852573Phase 1Not yet recruiting
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of ZM001 in systemic lupus erythematosus (SLE), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Incidence of Treatment Related adverse events at 28 days. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ZM001
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06852573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06852573.